Group 1 - The Zhejiang Securities Regulatory Bureau announced that Minsheng Securities, as the continuous supervision institution for Weikang Pharmaceutical Co., Ltd., violated regulations during its supervisory duties, particularly regarding the insufficient attention to the abnormal delays in construction projects and inadequate verification procedures [1] - The regulatory body highlighted that the conclusions drawn during the issuance of Weikang Pharmaceutical's 2023 annual continuous supervision documents were not cautious enough, indicating flaws in the internal controls of the investment banking business [1] - As a result of these violations, the Zhejiang Securities Regulatory Bureau decided to issue a warning letter as an administrative regulatory measure against Minsheng Securities and the responsible representatives Ren Shaozhong and Zhong Desong [1]
因在持续督导履职中出现违规，民生证券被监管出具警示函